Adding an FGF21 Drug to GLP-1 Therapy Slashed Liver Fat by 65% in MASH Patients
Efruxifermin added to GLP-1 receptor agonist therapy reduced liver fat by 65% in 12 weeks in patients with MASH and diabetes, compared to just 10% with GLP-1 drugs alone.
Quick Facts
What This Study Found
Adding efruxifermin (an FGF21 analog) to GLP-1 receptor agonist therapy in patients with MASH, liver fibrosis, and type 2 diabetes produced dramatic liver fat reduction: 65% decrease in hepatic fat fraction compared to just 10% with GLP-1 RA alone over 12 weeks (P < .0001). The combination also improved markers of liver injury, fibrosis, glucose metabolism, and lipid levels while maintaining the weight loss benefits of the GLP-1 RA.
Safety was a key focus: the combination appeared well-tolerated with a safety profile comparable to either drug alone. The most common side effects were mild-to-moderate GI events. Only one patient discontinued due to nausea, and there were no treatment-related serious adverse events. Nearly half the patients were on semaglutide, with the remainder on dulaglutide or liraglutide.
Key Numbers
n=31 · 2:1 randomization · efruxifermin 50 mg weekly · 12 weeks · HFF reduced 65% vs 10% placebo · P<.0001 · 48.4% on semaglutide · 45.2% on dulaglutide · 6.5% on liraglutide · 1 discontinuation (nausea) · 0 serious AEs
How They Did This
Double-blind, placebo-controlled phase 2b trial (Cohort D). Adults with type 2 diabetes and biopsy-confirmed MASH with fibrosis (F1-F3) on stable GLP-1 RA therapy were randomized 2:1 to receive efruxifermin 50 mg or placebo weekly for 12 weeks. Primary endpoint was safety/tolerability. Secondary endpoints included hepatic fat fraction (measured by MRI), liver injury biomarkers, fibrosis markers, and metabolic parameters.
Why This Research Matters
MASH (formerly NASH) affects millions of people worldwide and is closely tied to obesity and type 2 diabetes — the same patients increasingly being treated with GLP-1 drugs. While GLP-1 RAs provide modest liver benefits through weight loss, this study shows that adding efruxifermin dramatically amplifies liver fat reduction beyond what GLP-1 drugs achieve alone. This combination approach could be critical because MASH is becoming the leading cause of liver transplants, and effective combination therapies are urgently needed.
The Bigger Picture
The metabolic disease landscape is rapidly evolving toward combination therapies. GLP-1 drugs address weight and blood sugar but have limited direct effects on liver fibrosis. FGF21 analogs like efruxifermin target the liver directly, reducing fat accumulation and inflammation. Combining them could address the full spectrum of metabolic disease — obesity, diabetes, and liver disease — in a single regimen. This is especially important as MASH is on track to become the most common reason for liver transplantation.
What This Study Doesn't Tell Us
Small sample size (31 patients) limits statistical power for secondary endpoints. The 12-week duration is too short to assess fibrosis reversal on histology (biopsy). No liver biopsies were performed post-treatment — fibrosis changes were assessed by non-invasive markers only. The study was not powered to detect differences in clinical outcomes. The GLP-1 RA background varied (semaglutide, dulaglutide, liraglutide), making it difficult to determine if the combination works differently with different GLP-1 drugs.
Questions This Raises
- ?Will the 65% liver fat reduction translate to actual fibrosis reversal on biopsy in longer trials?
- ?Is the combination more effective with semaglutide specifically, or does the GLP-1 RA choice not matter?
- ?Could this combination prevent progression to cirrhosis in patients with early-stage MASH?
Trust & Context
- Key Stat:
- 65% liver fat reduction Efruxifermin added to GLP-1 therapy in 12 weeks, versus just 10% reduction with GLP-1 alone
- Evidence Grade:
- This is a randomized, double-blind, placebo-controlled phase 2b trial — strong study design — but with only 31 patients and a 12-week duration. The 'Moderate' grade reflects the rigorous design tempered by small sample size and short follow-up.
- Study Age:
- Published in 2025, this is a very current trial reflecting the latest in MASH combination therapy research. Larger phase 3 trials are expected to follow based on these promising results.
- Original Title:
- Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.
- Published In:
- Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 23(1), 103-113 (2025)
- Authors:
- Harrison, Stephen A(2), Frias, Juan P(5), Lucas, K Jean, Reiss, Gary, Neff, Guy, Bollepalli, Sureka, Su, Yan, Chan, Doreen, Tillman, Erik J, Moulton, Ali, de Temple, Brittany, Zari, Arian, Shringarpure, Reshma, Rolph, Timothy, Cheng, Andrew, Yale, Kitty
- Database ID:
- RPEP-11308
Evidence Hierarchy
Frequently Asked Questions
What is efruxifermin and how does it differ from GLP-1 drugs?
Efruxifermin is a modified version of FGF21, a hormone that directly targets the liver to reduce fat accumulation, inflammation, and scarring. GLP-1 drugs like semaglutide primarily work by reducing appetite and blood sugar, with indirect liver benefits from weight loss. Efruxifermin attacks liver disease more directly, which is why combining them produces much better liver results than either approach alone.
Why do MASH patients need something beyond GLP-1 drugs?
GLP-1 drugs help with weight loss and modestly reduce liver fat, but they have limited ability to reverse liver fibrosis (scarring) — which is what ultimately leads to cirrhosis and liver failure. MASH patients with significant fibrosis likely need a drug that directly targets liver pathology, not just weight and metabolism. The 65% liver fat reduction with efruxifermin added to GLP-1 therapy is far beyond what GLP-1 drugs achieve on their own.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-11308APA
Harrison, Stephen A; Frias, Juan P; Lucas, K Jean; Reiss, Gary; Neff, Guy; Bollepalli, Sureka; Su, Yan; Chan, Doreen; Tillman, Erik J; Moulton, Ali; de Temple, Brittany; Zari, Arian; Shringarpure, Reshma; Rolph, Timothy; Cheng, Andrew; Yale, Kitty. (2025). Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 23(1), 103-113. https://doi.org/10.1016/j.cgh.2024.02.022
MLA
Harrison, Stephen A, et al. "Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2025. https://doi.org/10.1016/j.cgh.2024.02.022
RethinkPeptides
RethinkPeptides Research Database. "Safety and Efficacy of Efruxifermin in Combination With a GL..." RPEP-11308. Retrieved from https://rethinkpeptides.com/research/harrison-2025-safety-and-efficacy-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.